CLINICAL TRIAL FACT SHEET
Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination with
Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma
This study is currently recruiting participants.
Sponsored by: Merck
Information provided by: Merck
ClinicalTrials.gov Identifier: NCT00773838
Merck study ID number: Vantage 095
Purpose
Study of vorinostat in combination with bortezomib in patients with relapsed or
refractory multiple myeloma after at least 2 prior treatment regimens.
Eligibility
18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Inclusion Criteria:
· Patient is 18 years of age or older
· Patient has an established diagnosis of multiple myeloma based on myeloma
diagnostic criteria and received at least 2 prior anti-myeloma regimens
· Patient must have adequate organ function
· Patient is refractory to prior bortezomib regimen and has also been exposed to prior IMiD
(thalidomide or lenalidomide)
Exclusion Criteria:
· Patient has known hypersensitivity to any components of bortezomib or vorinostat
· Patient has had a prior allogeneic bone marrow transplant or plans to undergo any type
of bone marrow transplantation within 4 weeks of the initiation of study therapy
· Patient has known hypersensitivity to any components of bortezomib or vorinostat.
Patient has active Hepatitis B or C, plasma cell leukemia, or is HIV positive
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00773838
Contacts: Contact: Toll Free Number 1-888-577-8839
Locations
United States, Indiana
Call for Information
Recruiting
Indianapolis, Indiana, United States, 46254
United States, Massachusetts
Call for Information
Recruiting
Boston, Massachusetts, United States, 02115
United States, Missouri
Call for Information
Recruiting
Jefferson City, Missouri, United States, 65109-0000
(continues on next page)
International Myeloma Foundation
12650 Riverside Drive, Suite 206, North Hol ywood, CA 91607 USA
Telephone: 800-452-CURE (2873) (USA & Canada)
818-487-7455 (worldwide) · TheIMF@myeloma.org · www.myeloma.org
United States, New Jersey
Call for Information
Recruiting
Hackensack, New Jersey, United States, 07601
United States, New York
Call for Information
Recruiting
Syracuse, New York, United States, 13210-0000
Call for Information
Recruiting
New York, New York, United States, 10011
United States, Tennessee
Call for Information
Recruiting
Knoxville, Tennessee, United States, 37920
Australia
Merck Sharp & Dohme (Australia) Pty Ltd.
Recruiting
South Granville, Australia, NSW 2142
Contact: David Woolner 64-9-523-6075
Belgium
Merck Sharp & Dohme B.V.
Recruiting
Bruxelles, Belgium, 1180
Contact: Nathalie Schrameijer 32-2-373-4310
Canada, Quebec
Merck Frosst Canada Ltd.
Recruiting
Kirkland, Quebec, Canada, H9H 3L1
Contact: Michel Cimon 514-428-2605
France
Laboratoires Merck Sharp & Dohme - Chibret
Recruiting
Paris Cedex 8, France, 75114
Contact: Jean-Marie Goehrs 33-1-4754-89-90
Italy
Merck Sharp & Dohme (Italia) S.P.A.
Recruiting
Roma, Italy, 191
Contact: Gianfranco Botta 39 06 36 191187
Korea, Republic of
MSD Korea Ltd.
Recruiting
Seoul, Korea, Republic of, 121-705
Contact: Steve Kim 82-2-6363-0241
Spain
Merck Sharp & Dohme De Espana, S.A.E.
Recruiting
Madrid, Spain, 28027
Contact: Jorge Gonzalez-Esteban 34-91-3210-728
Sponsors and Collaborators
Merck
Investigators
Study Director: Medical Monitor Merck
International Myeloma Foundation
12650 Riverside Drive, Suite 206, North Hol ywood, CA 91607 USA
Telephone: 800-452-CURE (2873) (USA & Canada)
818-487-7455 (worldwide) · TheIMF@myeloma.org · www.myeloma.org